CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Income Statement [Abstract]
Net revenues	$ 150,356	$ 126,051	$ 288,859	$ 248,233	$ 509,338
Cost of revenues	34,654	34,018	68,343	63,632	128,280
Gross profit	115,702	92,033	220,516	184,601	381,058
Operating costs and expenses:
Research, development and clinical studies	54,955	55,427	106,553	115,131	223,062
Sales and marketing	56,616	58,488	111,822	109,657	226,809
General and administrative	37,711	40,778	77,241	82,722	164,057
Total operating costs and expenses	149,282	154,693	295,616	307,510	613,928
Operating income (loss)	(33,580)	(62,660)	(75,100)	(122,909)	(232,870)
Financial income (expenses), net	10,851	8,756	20,729	17,925	41,130
Income (loss) before income tax	(22,729)	(53,904)	(54,371)	(104,984)	(191,740)
Income tax	10,646	3,514	17,764	5,495	15,303
Net income (loss)	$ (33,375)	$ (57,418)	$ (72,135)	$ (110,479)	$ (207,043)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.31)	$ (0.54)	$ (0.67)	$ (1.04)	$ (1.95)
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.31)	$ (0.54)	$ (0.67)	$ (1.04)	$ (1.95)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	107,700,284	106,289,073	107,483,241	105,979,791	106,391,178
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	107,700,284	106,289,073	107,483,241	105,979,791	106,391,178